Search

Your search keyword '"D'Ardìa S"' showing total 4 results
Start Over Author "D'Ardìa S"
4 results on '"D'Ardìa S"'

3. Validation of National Early Warning Score and Quick Sequential (sepsis-related) Organ Failure Assessment in acute myeloid leukaemia patients treated with intensive chemotherapy.

Author

Frairia C, Nicolino B, Secreto C, Messa E, Arrigo G, Busca A, Cerrano M, D'Ardìa S, Dellacasa C, Evangelista A, Freilone R, Giai V, Priolo G, Urbino I, and Audisio E

Subjects
Adult, Humans, Organ Dysfunction Scores, Retrospective Studies, Intensive Care Units, Fever diagnosis, Fever etiology, Prognosis, ROC Curve, Early Warning Score, Sepsis complications, Leukemia, Myeloid, Acute complications, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute drug therapy
Abstract

Objectives: Chemotherapy-induced neutropenia in acute myeloid leukaemia (AML) is a risk factor for life-threatening infections. Early diagnosis and prompt interventions are associated with better outcomes, but the prediction of infection severity remains an open question. Recently, National Early Warning Score (NEWS) and quick sequential organ failure assessment (qSOFA) scores were proposed as warning clinical instruments predicting in-hospital mortality, but their role in the haematological context is still unknown., Methods: We retrospectively assess the predictive role of NEWS and qSOFA in a large and homogeneous cohort of adult AML patients treated with intensive chemotherapy. In a total of 1048 neutropenic episodes recorded in 334 consecutive patients, the scores were applied to predict outcomes on the same day of fever onset, and after 24 and 48 h from score calculation., Results: Both NEWS and qSOFA significantly predicted death, with more accuracy on the same day (NEWS AUROC 0.984 and qSOFA AUROC 0.969) and after 24 h (NEWS AUROC 0.928 and qSOFA AUROC 0.887), while remained moderately accurate after 48 h. Furthermore, also ICU admission was accurately predicted at fever onset and after 24 h., Conclusions: Both scores were useful tools in the management of post chemotherapy neutropenic febrile AML patients., (© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

4. Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.

Author

Arrigo G, D'Ardìa S, Audisio E, Cerrano M, Freilone R, Giai V, Secreto C, Urbino I, and Frairia C

Subjects
Aged, Aniline Compounds, Azacitidine, Cytarabine, Daunorubicin, Female, Humans, Mutation, Pyrazines, Recurrence, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics, fms-Like Tyrosine Kinase 3 genetics
Abstract

Extramedullary relapse of acute myeloid leukemia (AML) is not a rare event, and the FMS-like tyrosine kinase 3 (FLT3) mutation is a well-known risk factor. Gilteritinib is approved for relapsed/refractory FLT3+ AML, but its efficacy in extramedullary relapse is still undefined. Here, we present the case of a 69-year-old woman with therapy-related nucleophosmin-1 and FLT3-internal tandem duplication (FLT3-ITD) positive AML treated with induction and consolidation with CPX-351 (liposomal daunorubicin plus cytarabine) followed by off-label azacitidine maintenance who obtained a complete remission (CR) with persistent measurable residual disease. After 19 months of CR, she experienced an isolated breast relapse of FLT3-ITD+ AML. She was started on single-agent gilteritinib, resulting in a rapid and persistent complete regression of the breast nodule. Targeted therapy with gilteritinib for relapsed/refractory FLT3-ITD+ AML can be effective in isolated extramedullary relapse., (© 2022 S. Karger AG, Basel.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results